$15.19
1.00%
Nasdaq, Sep 29, 04:00 pm EDT. Closed.
ISIN
IL0011839383
Symbol
DRTS

Alpha Tau Medical Stock price

$15.19
+1.08 7.65% 1M
+8.64 131.91% 6M
+10.24 206.87% YTD
+10.94 257.41% 1Y
+11.40 300.79% 3Y
+5.35 54.37% 5Y
+5.09 50.40% 10Y
+5.09 50.40% 20Y
Nasdaq, Closing price Tue, Sep 29 2026
+0.15 1.00%
ISIN
IL0011839383
Symbol
DRTS

Is Alpha Tau Medical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.3b
Net debt
positive
Cash
$76.4m
Shares outstanding
90.2m
Valuation (TTM | estimate)
P/E
negative
P/S
- | 1,438.3
EV/Sales
- | 1,366.6
EV/FCF
-
P/B
20.3
Financial Health
Equity Ratio
73.0%
Return on Equity
-55.3%
ROCE
-47.1%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $976.7k
EBITDA
-
EBIT
$-46.3m
Net Income
$-56.9m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-25.4%
Net Income
-75.2%
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
-
Short interest
5.4%
Employees
121
Rev per Employee
$0.0

Alpha Tau Medical Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Alpha Tau Medical forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Alpha Tau Medical forecast:

Buy
82%
Hold
18%

Financial data from Alpha Tau Medical

Mar '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
14% 14%
-
- Research and Development Expense 36 36
29% 29%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -46 -46
25% 25%
-
Net Profit -57 -57
75% 75%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alpha Tau Medical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alpha Tau Medical Stock News

Neutral
GlobeNewsWire
●
about one month ago
- IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total of 48 treated patients, driven by overwhelming demand from patients and clinicians - - Alpha DaRT is delivered as a one-time add-on alongside standard first-line chemotherapy, a...
Neutral
GlobeNewsWire
●
about 2 months ago
JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.
Neutral
GlobeNewsWire
●
2 months ago
- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) - - Among all nine evaluable patients, the combination produced a systemic objecti...
More Alpha Tau Medical News

Company Profile

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Head office Israel
CEO Mr. Sofer
Employees 121
Founded 2015
Website www.alphatau.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today